tbuckley/cabot-search huggingface dataset:
B7H3-Directed Intraperitoneal Radioimmunotherapy With Radioiodinated Omburtamab for Desmoplastic Small Round Cell Tumor and Other Peritoneal Tumors: Results of a Phase I Study
Authors: Shakeel Modak, Pat Zanzonico, Milan Grkovski, Emily K. Slotkin, Jorge A. Carrasquillo, Serge K. Lyashchenko, Jason S. Lewis, Irene Y. Cheung, Todd Heaton, Michael P. LaQuaglia, Nai-Kong V. Cheung, Neeta Pandit-Taskar
Journal: Journal of Clinical Oncology (2020)

Desmoplastic small round cell tumor (DSRCT), a rare sarcoma of adolescents/young adults primarily involving the peritoneum, has a long-term survival of < 20% despite aggressive multimodality treatment. B7H3 is expressed on DSRCT cell surface, providing a target for antibody-based immunotherapy.In this phase I study, we evaluated the safety, pharmacokinetics, and biodistribution of intraperitoneal (IP) radioimmunotherapy (RIT) with the anti-B7H3 murine monoclonal antibody 131I-omburtamab in patients with DSRCT or other B7H3-expressing tumors involving the peritoneum. After thyroid blockade, patients received 131I-omburtamab as a single IP injection at escalated activities from 1.11 to 3.33/GBq/m2. A prior tracer dose of IP 74 MBq124I-omburtamab was used for radioimmuno-positron emission tomography imaging. Each injection was followed by IP saline infusion.Fifty-two patients (48, three, and one with DSRCT, peritoneal rhabdomyosarcoma, and Ewing sarcoma, respectively) received IP 131I-omburtamab administered on an outpatient basis. Maximum tolerated dose was not reached; there were no dose-limiting toxicities. Major related adverse events were transient: grade 4 neutropenia (n = 2 patients) and thrombocytopenia (n = 1), and grade 1 (10%) and grade 2 (52%) pain lasting < 2 hours related to saline infusion. Hypothyroidism was not observed, and antidrug antibody was elicited in 5%. Mean (± SD) projected peritoneal residence time was 22.4 ± 7.9 hours. Mean projected absorbed doses for 131I-omburtamab based on 124I-omburtamab dosimetry to normal organs were low and well within tolerable limits. More than 80% 131I remained protein bound in blood 66 hours after RIT. On the basis of peritoneal dose and feasibility for outpatient administration, the recommended phase II activity was established at 2.96 GBq/m2. Patients with DSRCT receiving standard whole-abdominal radiotherapy after RIT did not experience unexpected toxicity.IP RIT 131I-omburtamab was well tolerated with minimal toxicities. Radiation exposure to normal organs was low, making combination therapy with other anticancer therapies feasible.
Single-Agent Mosunetuzumab Is a Promising Safe and Efficacious Chemotherapy-Free Regimen for Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
Authors: Adam J Olszewski, Abraham Avigdor, Sunil Babu, Itai Levi, Uri Abadi, Houston Holmes, Matthew McKinney, Ron McCord, Yuying Xie, Cindy Chen, Kati Sarouei, Naseer Qayum, Carol O'Hear, Gila Sellam, Herbert Eradat
Journal: Blood (2020)
Use of Genetically Informed Methods to Clarify the Nature of the Association Between Cannabis Use and Risk for Schizophrenia
Authors: Nathan A. Gillespie, Kenneth S. Kendler
Journal: JAMA Psychiatry (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Psychiatry HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Psychiatry journal
ABL1 Kinase Plays an Important Role in Spontaneous and Melphalan-Induced Genomic Instability in Multiple Myeloma: Potential Therapeutic Application
Authors: Subodh Kumar, Srikanth Talluri, Jiangning Zhao, Chengcheng Liao, Lakshmi B. Potluri, Leutz Buon, Shidai Mu, Jialan Shi, Mychell Neptune-Buon, Chandraditya Chakraborty, Yu-Tzu Tai, Mehmet K. Samur, Mariateresa Fulciniti, Rao Prabhala, Masood A. Shammas, Nikhil C. Munshi
Journal: Blood (2020)
The Comparison of Results of Autologous Transplantation Using Non-Cryopreserved and Cryopreserved Hematopoietic Stem Cells (HSC)
Authors: Sergei Voloshin, Andrey Garifullin, Sergey Linnikov, Anastasiya Kuzyaeva, Vasily Shuvaev, Valentina Balashova, Georgiy Rysev, Alexander Chechetkin, Zanna Chebukina
Journal: Blood (2020)
Abstract 465: A 3D Bioprinted Human Cardiac Cell Platform to Model the Pathophysiology of Diabetes
Authors: Binata Joddar, Shweta AnilKumar, Matthew Alonzo, Vikram Thakur, MUNMUN CHATTOPADHYAY
Journal: Circulation Research (2020)

Type-II diabetes (T2D) patients affected by underlying hyperglycemic (high glucose/blood sugar) conditions often suffer from cardiac atrophy, resulting in tissue mass reduction and debilitating cardiac health. To understand pathophysiological mechanisms during progression of cardiac atrophy, a 3D bioprinted organoid platform was developed from a mixture of hydrogels containing human cardiac cells, including cardiomyocytes (CM), fibroblasts (CF) and endothelial cells (EC), to mimic the functionality of the in-vivo tissue. The organoids were cultured using normoglycemic- or hyperglycemic-conditions. The expression of essential biomarkers in these organoids, for myocardin (Myocd), troponin-I (TRP-I), fibroblast protein-1 (FSP-1) and endothelin-1 (ET-1) was confirmed. To assess the physiological cellular connections during hyperglycemia, the presence of Connexin-43 (CX-43) was assessed in the presence of a CX-43 blocker, gap26. Epigenomic tools were used to simultaneously interrogate histone-modifications by histone 3 lysine 9 mono-methylation (H3K9me1) along with the co-regulation of inflammatory mediators, such as the high mobility group box 1 (HMGB1) and toll like receptor 4 (TLR4) in the cardiac organoids cultured using normal versus hyperglycemic conditions. Organoids exposed to high glucose showed an increased expression of H3K9me1 as well as inflammatory mediators HMGB1 and TLR4. Hyperglycemia also exhibited alterations in expression of Myocd and FSP-1 in the organoids, compared to normoglycemic conditions. Treatment with gap26 affected the CX-43 expression significantly, in organoids cultured under hyperglycemia suggesting that high glucose conditions associated with prolonged diabetes may lead to compromised CM-CF coupling, essential for maintenance of cardiac functionality. Increased levels of H3K9me1 suggest decreased expression of Myocd, which may lead to CM degeneration. Epigenetic modifications including alterations in histone methylation in regulation of the myocardial genes and gap junction proteins under hyperglycemic conditions, may lead to cardiac atrophy. We expect to establish an actual T2D patient iPSC cell derived cardiac platform, to offer new therapeutic opportunities within the field.
A Randomized Phase 2 Study of Pevonedistat, Venetoclax, and Azacitidine Versus Venetoclax Plus Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy
Authors: Nicholas J. Short, Farhad Sedarati, Dan Zhao, Olga Tsukurov, Sharon Friedlander, Douglas V. Faller
Journal: Blood (2020)
Describing Treatment of Primary Mediastinal Large B Cell Lymphoma Using Rigorously Defined Molecular Classification: A Retrospective Analysis
Authors: Carla Casulo, Myla Strawderman, Raphael Steiner, Carolyne Delage, Tina Faugh, Matthew J. Maurer, Brian K. Link, Allison C. Rosenthal, Colleen Ramsower, Richard Burack, Sergei Syrbu, Andrew L. Feldman, Philip J Rock, James R. Cerhan, Christopher Flowers, Lisa M. Rimsza, Jonathan W. Friedberg
Journal: Blood (2020)
PHI-101 Is a Potent Third-Generation FLT3 Inhibitor Developed to Overcome Resistance in Acute Myeloid Leukemia
Authors: Ky-Youb Nam, Jeejin Im, June H-J H-J Han, Kyu-Tae Kim, Jeong-Hyeok Yoon, Hanna Cho, Seung-Hye Choi, David Young, Bao Nguyen, Ruiqi Zhu, Li Li, Donald Small, Taebo Sim
Journal: Blood (2020)
Telework Before Illness Onset Among Symptomatic Adults Aged ≥18 Years With and Without COVID-19 in 11 Outpatient Health Care Facilities — United States, July 2020
Authors: Kiva A. Fisher, Samantha M. Olson, Mark W. Tenforde, Leora R. Feldstein, Christopher J. Lindsell, Nathan I. Shapiro, D. Clark Files, Kevin W. Gibbs, Heidi L. Erickson, Matthew E. Prekker, Jay S. Steingrub, Matthew C. Exline, Daniel J. Henning, Jennifer G. Wilson, Samuel M. Brown, Ithan D. Peltan, Todd W. Rice, David N. Hager, Adit A. Ginde, H. Keipp Talbot, Jonathan D. Casey, Carlos G. Grijalva, Brendan Flannery, Manish M. Patel, Wesley H. Self, Kimberly W. Hart, Robert McClellan, Hsi-nien Tan, Adrienne Baughman, Nora A. Hennesy, Brittany Grear, Michael Wu, Kristin Mlynarczyk, Luc Marzano, Zuwena Plata, Alexis Caplan, E. Ogokeh, Emily R. Smith, Sara S. Kim, Eric P. Griggs, Bridget Richards, Sonya Robinson, Kaylee Kim, Ahmed M. Kassem, Courtney N. Sciarratta, Paula L. Marcet
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

Since March 2020, large-scale efforts to reduce transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), have continued. Mitigation measures to reduce workplace exposures have included work site policies to support flexible work site options, including telework, whereby employees work remotely without commuting to a central place of work.* Opportunities to telework have varied across industries among U.S. jobs where telework options are feasible (1). However, little is known about the impact of telework on risk for SARS-CoV-2 infection. A case-control investigation was conducted to compare telework between eligible symptomatic persons who received positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test results (case-patients, 153) and symptomatic persons with negative test results (control-participants, 161). Eligible participants were identified in outpatient health care facilities during July 2020. Among employed participants who reported on their telework status during the 2 weeks preceding illness onset (248), the percentage who were able to telework on a full- or part-time basis was lower among case-patients (35%; 42 of 120) than among control-participants (53%; 68 of 128) (p<0.01). Case-patients were more likely than were control-participants to have reported going exclusively to an office or school setting (adjusted odds ratio [aOR] = 1.8; 95% confidence interval [CI] = 1.2-2.7) in the 2 weeks before illness onset. The association was also observed when further restricting to the 175 participants who reported working in a profession outside the critical infrastructure† (aOR = 2.1; 95% CI = 1.3-3.6). Providing the option to work from home or telework when possible, is an important consideration for reducing the risk for SARS-CoV-2 infection. In industries where telework options are not available, worker safety measures should continue to be scaled up to reduce possible worksite exposures.
Prognostic Prediction Clinical-Molecular Model for Allogeneic Transplant Outcomes in Patients with Myelodysplastic Syndrome
Authors: Zixian Liu, Erlie Jiang, Yi He, Lixia Liu, Chengcheng Wang, Jialin Wei, Donglin Yang, Tao Zhou, Aiming Pang, Yong Huang, Rongli Zhang, Qiaoling Ma, Mengmeng Zhang, Feng Lou, Shanbo Cao, Qianqian Wang, Weihua Zhai, Sizhou Feng, Zhijian Xiao, Ming-Zhe Han
Journal: Blood (2020)
The Clonal Trajectories of <i>SF3B1</i> Mutations in Myeloid Neoplasia
Authors: Hassan Awada, Cassandra M. Kerr, Vera Adema, Carmelo Gurnari, Simona Pagliuca, Heesun J. Rogers, Hetty E. Carraway, Mikkael A. Sekeres, Jaroslaw P. Maciejewski, Valeria Visconte
Journal: Blood (2020)
Focal, Symptomatic Bone Marrow Lesions in Waldenström Macroglobulinaemia Characterised By Dense Infiltration with Lymphoplasmacytic Lymphoma: A Newly Defined Indication for Systemic Treatment
Authors: Suzanne Arulogun, Maaz Ali Abbasi, Sabine Pomplun, Aideen Therese O'Neill, Simon Wan, Irfan Kayani, Shirley D'Sa
Journal: Blood (2020)
DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Authors: Vu Hong, Ravi Krishna Babu, Cecile Blaustein, Sophia Nguyen, Venkateshwar Rao, Will Savage, Brian MacDonald, Maria G. Beconi, Srikanth Venkatraman
Journal: Blood (2020)
Clonal Hematopoiesis and Its Implications for Flow Cytometric Assessment of Measurable Residual Disease in Patients with <i>NPM1-</i>mutated Acute Myeloid Leukemia
Authors: Sanam Loghavi, Courtney D. DiNardo, Koichi Takahashi, Rashmi Kanagal-Shamanna, Tomoyuki Tanaka, Ken Furudate, Nicholas J. Short, Tapan M. Kadia, Marina Konopleva, Noushin Farnoud, Sherry A. Pierce, Joseph D. Khoury, Jeffrey L. Jorgensen, Keyur P. Patel, L. Jeffrey Medeiros, Hagop M. Kantarjian, Farhad Ravandi, Sa A Wang
Journal: Blood (2020)
The Emerging and Promising Role of Care for Cardiometabolic Syndrome in Prostate Cancer
Authors: Atsushi Tanaka, Koichi Node
Journal: JACC CardioOncology (2019)

Prostate cancer is characterized clinically by slow growth and a relatively good prognosis, but its incidence is increasing rapidly in Japan ([1][1],[2][2]). A recent retrospective analysis from the U.S. National Inpatient Sample also demonstrated that prostate cancer was among the most common
Study of Treatment Complications in Oncology / Hematology Patients: Protocol for a Prospective and Interventional Cohort Study from the Pasca Program
Authors: Mauricette Michallet, Romain Buono, Mohamad Sobh, Solene Poirey, Emmanuelle Nicolas-Virelizier, Souad Assaad, Amine Belhabri, Laure Lebras, Yann Guillermin, Philippe Rey, Aude Flechon, Helen Boyle, Franck E Nicolini, Audrey Couillet, Gisele Chvetzoff, Jean-Yves Blay, Beatrice Fervers, Anne-Sophie Michallet
Journal: Blood (2020)
Residential context and COVID-19 mortality among adults aged 70 years and older in Stockholm: a population-based, observational study using individual-level data
Authors: Maria Brandén, Siddartha Aradhya, Martin Kolk, Juho Härkönen, Sven Drefahl, Bo Malmberg, Mikael Rostila, Agneta Cederström, Gunnar Andersson, Eleonora Mussino
Journal: The Lancet Healthy Longevity (2020)

Housing characteristics and neighbourhood context are considered risk factors for COVID-19 mortality among older adults. The aim of this study was to investigate how individual-level housing and neighbourhood characteristics are associated with COVID-19 mortality in older adults.
Abstract 525: Adult Inducible Deletion of Endothelial Hypoxia-inducible Factor-2α Exaggerates Myocardial Infarction Induced Heart Failure and Cardiac Microvascular Barrier Dysfunction
Authors: Lizhuo Ai, Lifeng Liu, rongxue wu, Albert Sitikov, Devin Harrison, Stephanie A Besser, Yun Fang, james K Liao, Rongxue Wu
Journal: Circulation Research (2020)

Background: Myocardial ischemia occurs during myocardial infarction results in the stabilization of Hypoxia-inducible factors (HIFs). Hif2α expresses profoundly in vascular endothelial cells (EC), and its embryonic deletion increases vessel permeability. It has been shown that HIF2a is protective from renal and pulmonary injury. However, the direct role of ecHIF2α in ischemia heart disease is unknown. We hypothesized that ecHIF2a expression in response to myocardial infarction (MI) protects cardiac barrier dysfunction and against heart failure. Methods and Results: We generated the Inducible endothelial-specific knockout mice (ecHIF2a -/- ) by crossing Hif2a flox/flox mice with Cre ERT2 mice under the VE-cadherin promoter. Followed with MI, ecHIF2a -/- mice displayed worsened cardiac function determined by echocardiography, and they had increased mortality as compared to the controls. In vitro, we used primary mouse cardiac microvascular endothelial cells (mCMVEC) from ecHIF2a -/- mouse hearts. We found that under hypoxia condition or 1mM Dimethyloxalylglycine treatment, the deficiency of HIF2a in the mCMVEC increased endothelial permeability determined by trans-endothelial electrical resistance. The knocking down of HIF2a in HUVECs induced by a HIF2a siRNA led to impaired tube formation accessed by the significant reduction in total node counts, junctions, meshes, and full tube length compared to control-siRNA treated cells. HIF2α deletion and hypoxia both reduced endothelial cell migration, and interestingly, the retarded HIF2α-/- ECs migration seems to be independent of hypoxia. Moreover, apoptosis assay showed that ecHIF2a -/- ECs increased cell early apoptotic stage compared to WT in hypoxic conditions, but not in normoxia indicating the critical role of HIF2α in ECs survival during cardiac ischemia. Finally, several increased markers of inflammation, such as ICAM-1 and VCAM-1, are associated with HIF2a deletion. Conclusion: These data revealed an essential role of HIF2α in protecting cardiac remodeling in response to MI, which might through promoting endothelial cell migration, barrier function, as well as vascularization. Thus, HIF2α is a potential therapeutic target in the treatment of ischemic heart disease.
Active Akt signaling triggers CLL toward Richter transformation via overactivation of Notch1
Authors: Vivien Kohlhaas, Stuart James Blakemore, Mona Al-Maarri, Nadine Nickel, Martin Pal, Andreas Roth, Nadine Hövelmeyer, Stephan C. Schäfer, Gero Knittel, Philipp Lohneis, Milos Nikolic, Janica L. Wiederstein, Marek Franitza, Theodoros Georgomonolis, Nina Reinart, Marco Herling, Carmen Herling, Elena M. Hartmann, Andreas Rosenwald, Wolfram Klapper, Reinhard Büttner, Riccardo Moia, Davide Rossi, Renzo Boldorini, Gianluca Gaidano, Lukas P. Frenzel, Hans Christian Reinhardt, Jens C. Brüning, Michael Hallek, Marcus Krüger, Martin Peifer, Christian P. Pallasch, F. Thomas Wunderlich
Journal: Blood (2020)
Venetoclax, FLT3 Inhibitor and Decitabine in <i>FLT3</i>mut Acute Myeloid Leukemia: Subgroup Analysis of a Phase II Trial
Authors: Abhishek Maiti, Courtney D. DiNardo, Farhad Ravandi, Naveen Pemmaraju, Gautam Borthakur, Prithviraj Bose, Ghayas C. Issa, Tapan M. Kadia, Nicholas J. Short, Musa Yilmaz, Guillermo Montalban-Bravo, Alessandra Ferrajoli, Elias Jabbour, Nitin Jain, Maro Ohanian, Koichi Takahashi, Philip A. Thompson, Caitlin R. Rausch, Kathryn S Montalbano, Sherry A. Pierce, Hagop M. Kantarjian, Naval Daver, Marina Konopleva
Journal: Blood (2020)
Final Primary Results from the Defifrance Registry Study: Effectiveness and Safety of Defibrotide in the Treatment of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Hematopoietic Cell Transplantation
Authors: Mohamad Mohty, Ibrahim Yakoub-Agha, Myriam Labopin, Didier Blaise, Delphine Lebon, Virginie Gandemer, Sebastien Maury, Cecile Renard, Charlotte Jubert, Robert J. Ryan, Virginie Bouvatier, Jean-Hugues Dalle, Regis Peffault de Latour
Journal: Blood (2020)
Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US
Authors: Jeromie Ballreich, Omar Mansour, Ellen Hu, Francine Chingcuanco, Harold A. Pollack, David W. Dowdy, G. Caleb Alexander
Journal: JAMA Network Open (2020)

<h3>Importance</h3> The US opioid epidemic is complex and dynamic, yet relatively little is known regarding its likely future impact and the potential mitigating impact of interventions to address it. <h3>Objective</h3> To estimate the future burden of the opioid epidemic and the potential of interventions to address the burden. <h3>Design, Setting, and Participants</h3> A decision analytic dynamic Markov model was calibrated using 2010-2018 data from the National Survey on Drug Use and Health, Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey, the US Census, and National Epidemiologic Survey on Alcohol and Related Conditions–III. Data on individuals 12 years or older from the US general population or with prescription opioid medical use; prescription opioid nonmedical use; heroin use; prescription, heroin, or combined prescription and heroin opioid use disorder (OUD); 1 of 7 treatment categories; or nonfatal or fatal overdose were examined. The model was designed to project fatal opioid overdoses between 2020 and 2029. <h3>Exposures</h3> The model projected prescribing reductions (5% annually), naloxone distribution (assumed 5% reduction in case-fatality), and treatment expansion (assumed 35% increase in uptake annually for 4 years and 50% relapse reduction), with each compared vs status quo. <h3>Main Outcomes and Measures</h3> Projected 10-year overdose deaths and prevalence of OUD. <h3>Results</h3> Under status quo, 484 429 (95% confidence band, 390 543-576 631) individuals were projected to experience fatal opioid overdose between 2020 and 2029. Projected decreases in deaths were 0.3% with prescribing reductions, 15.4% with naloxone distribution, and 25.3% with treatment expansion; when combined, these interventions were associated with 179 151 fewer overdose deaths (37.0%) over 10 years. Interventions had a smaller association with the prevalence of OUD; for example, the combined intervention was estimated to reduce OUD prevalence by 27.5%, from 2.47 million in 2019 to 1.79 million in 2029. Model projections were most sensitive to assumptions regarding future rates of fatal and nonfatal overdose. <h3>Conclusions and Relevance</h3> The findings of this study suggest that the opioid epidemic is likely to continue to cause tens of thousands of deaths annually over the next decade. Aggressive deployment of evidence-based interventions may reduce deaths by at least a third but will likely have less impact for the number of people with OUD.
Abstract IA11: Detecting and targeting cellular heterogeneity of the lymphoid blood malignancies
Authors: Catherine J. Wu
Journal: Cancer Research (2020)

Abstract Multiple lines of evidence have convincingly demonstrated tumor neoantigens as an important class of immunogenic tumor antigens, and have motivated the development of personalized cancer neoantigen targeting approaches. Neoantigens arise from amino acid changes encoded by somatic mutations in the tumor cell and have the potential to bind to and be presented by personal HLA molecules. Because the immune response has the capacity of addressing multiple tumor neoantigens simultaneously, immune-based therapy has a potential for directly address tumor heterogeneity. As a field, we have now successfully moved beyond the first wave proof-of-concept studies that have demonstrated the safety, feasibility and high immunogenicity of these personalized neoantigen-targeting vaccines. An imperative now is to address the challenges of discovering and optimizing the selection of antigens to target, the delivery approach, and extending this promising approach to a broader array of cancer settings. Citation Format: Catherine J. Wu. Detecting and targeting cellular heterogeneity of the lymphoid blood malignancies [abstract]. In: Proceedings of the AACR Virtual Special Conference on Tumor Heterogeneity: From Single Cells to Clinical Impact; 2020 Sep 17-18. Philadelphia (PA): AACR; Cancer Res 2020;80(21 Suppl):Abstract nr IA11.
Cell of Origin Impacts Δsuvmax Cutoff for Prediction of Relapse in Patients with Diffuse Large B-Cell Lymphoma
Authors: Carolina Feres, Leonardo Javier Arcuri, Larissa LC Teixeira, Mariana Nassif Kerbauy, Denise Cunha Pasqualin, Alanna MPS Bezerra, Guilherme de Carvalho Campos Neto, Rafael Fernandes Nunes, Aline Fernanda Ramos, Michelle De Paula Jacinto, Guilherme Fleury Perini, Nelson Hamerschlak
Journal: Blood (2020)